单中心经验:免疫检查点抑制剂治疗后接受化疗的转移性尿路上皮癌患者
该单中心回顾性分析纳入29例免疫检查点抑制剂(ICI)进展后接受化疗(CT)的转移性尿路上皮癌(MUC)患者,分为未接受过化疗组(n=17)和化疗预处理组(n=12)。未接受过化疗组部分缓解率53%、中位无进展生存期6.4个月,化疗预处理组部分缓解率17%、中位无进展生存期4.4个月;作者认为化疗与ICI可序贯使用,但多数患者无法获得长期持久缓解。
要点
- ICI进展后接受CT的MUC患者中,未接受过化疗组部分缓解率53%,化疗预处理组17%。
- 中位无进展生存期未接受过化疗组6.4个月,化疗预处理组4.4个月。
- 两组共10例对CT有反应者的中位缓解持续时间为8.1个月。
核心结论
- 在既往化疗暴露后,CT与ICI可以序贯使用,但多数患者不能由此获得长期持久缓解。
研究设计与样本
- 回顾性单中心分析,纳入29例ICI进展后接受CT的转移性尿路上皮癌(MUC)患者。
- 患者分为未接受过化疗组(n=17)和化疗预处理组(n=12,先接受铂类化疗、进展后使用ICI)。
- 评估指标为缓解率(RR)、无进展生存期(PFS)和缓解持续时间(DOR)。
- 中位随访17.0个月(四分位距9.1-20.5个月)。
主要发现
- 未接受过化疗组(n=17):部分缓解53%,疾病稳定18%,疾病进展29%。
- 化疗预处理组(n=12):部分缓解17%,疾病稳定67%,疾病进展16%。
- 中位PFS:未接受过化疗组6.4个月(95%CI 3.8-9.1),化疗预处理组4.4个月(95%CI 1.5-7.3)。
- 两组共10例对CT有反应者的中位DOR为8.1个月(范围5.1-11.1个月)。
- 未接受过化疗组38%、化疗预处理组17%的患者在ICI后CT期间进行了剂量下调。
临床怎么用
- 作者认为,在既往化疗暴露后,CT与ICI可以序贯使用,但多数患者不能由此获得长期持久缓解。
- 作者在患者摘要中指出,患者可以安全地接受进一步化疗,但化疗的正面效应在多数患者中不会持久。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are few data on outcomes for patients with metastatic urothelial carcinoma (MUC) who receive chemotherapy (CT) after progression on immune checkpoint inhibitors (ICIs). We carried out a retrospective single-centre analysis of MUC patients who progressed after ICI and then received CT. Patients fell into two groups: CT-naive (no prior-CT) and CT-pretreated (platinum-based CT followed by ICI on progression). The response rate (RR), progression-free survival (PFS), and duration of response (DOR) were assessed. A total of 29 patients received CT following progression on ICI. The median follow-up was 17.0mo (interquartile range 9.1-20.5mo). In the CT-naive group (n=17), 53% had a partial response, 18% had stable disease, and 29% had progressive disease. In the CT-pretreated group (n=12) 17% had a partial response, 67% had stable disease, and 16% had progressive disease. The median PFS was 6.4mo (95% confidence interval [CI] 3.8-9.1) in the CT-naive and 4.4mo (95% CI 1.5-7.3) in the CT-pretreated group. The median DOR was 8.1mo (range 5.1-11.1) among the ten patients with a response to CT after ICI in both groups. Some 38% of patients in the CT-naive and 17% in the CT-pretreated group had dose reductions on post-ICI CT. CT and ICI can be sequenced after previous chemotherapy exposure, although this does not induce long-term durable remissions in most patients. PATIENT SUMMARY: We looked at outcomes for patients with metastatic bladder cancer who received chemotherapy after the cancer got worse while on immunotherapy. We found that patients can be safely treated with further chemotherapy. However, the positive effects of chemotherapy will not be durable in the majority of patients.
引用
- Lam JM, Liu WK, Powles T, et al. Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition. Eur Urol Oncol. 2019. PMID: 31151926. doi:10.1016/j.euo.2019.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。